New drug target identified to potentially fight neuroblastoma
Researchers have revealed that the protein ALYREF promotes the effects of the neuroblastoma gene, MYCN, making it a target.
List view / Grid view
Researchers have revealed that the protein ALYREF promotes the effects of the neuroblastoma gene, MYCN, making it a target.
In this ebook, find articles exploring some of the assays used to identify the most promising COVID-19 drugs and discussing the development of a novel assay to reveal potential peptide therapeutics for cancer.
Researchers have shown that SARS-CoV-2 infects mouth cells, which could inform the development of treatments against the oral symptoms of COVID-19.
A team has shown that tilorone, quinacrine and pyronaridine are effective at inhibiting the replication of SARS-CoV-2 in vitro.
Professor David Merryman explains how his team targeted the serotonin 2B receptor in animal models to preserve cardiac function six weeks after a heart attack.
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Having revealed the activation mechanism and functional states of A2AR signalling, a GPCR, researchers say this could aid drug discovery.
Researchers are using a new method to isolate the complex between SARS-CoV-2 and the ACE2 receptor to keep it embedded in the cell membrane.
Researchers have shown that the PLpro coronavirus enzyme presents a possible target in the fight against COVID-19.
A novel machine learning method called DeepBAR could accelerate drug discovery and protein engineering, researchers say.
Using X-ray crystallography and simulations, researchers have shown that APT2 is a hybrid between a lipid carrier protein and a hydrolase.
A team has revealed a function of ADAR1, responsible for RNA editing, discovering an isoform used for cancer growth, making it a drug target.
Researchers have produced the first 3D image of the Mediator-bound pre-initiation complex, key in the regulation of gene expression.
Researchers have developed a new tool that can add or remove sugar from proteins, which could be used to treat currently "undruggable" targets.